55 results
8-K
EX-99.1
ALKS
Alkermes plc
23 Oct 23
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
8:27am
a pharmacokinetic and pharmacodynamic profile that supports once-daily, oral dosing.
“Narcolepsy is a serious, chronic, neurological disease that impairs
8-K
EX-99.1
ALKS
Alkermes plc
1 Jun 21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
7:09am
disorder are complex, chronic diseases and there remains a persistent need for new medications with proven efficacy and safety. Olanzapine, a highly … for cardiopulmonary resuscitation.
Risk of Resuming Opioids in Patients with Prior Opioid Use
Patients with a history of chronic opioid use prior to treatment
8-K
EX-99.1
ALKS
Alkermes plc
25 Mar 21
Regulation FD Disclosure
12:00am
and modulate reward pathways Alexandre, Chloe et al. Current opinion in neurobiology. 2013;23:752-9
Narcolepsy: A Chronic Neurological Disorder … Chronic neurological disorder characterized by daytime sleepiness and sudden transitions into sleep1 Affects ~200,000 people in U.S. and 3M people
8-K
EX-99.1
k0q5fma vw
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am
8-K
EX-99.1
esk pfqik68byptd
13 Jan 20
Regulation FD Disclosure
7:07am
8-K
EX-99.1
0jh25zv u2hi1
18 Nov 19
Alkermes to Acquire Rodin Therapeutics
7:16am
8-K
EX-99.1
6n47oyaa
30 Oct 19
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
7:43am
8-K
EX-99.1
wtdyecxnrenn8g e2
13 Sep 19
Departure of Directors or Certain Officers
7:22am
8-K
EX-99.1
rv4 urllzgfsi6
30 Jul 19
Regulation FD Disclosure
7:46am
8-K
EX-99.1
bbgrbdnjmwdmk
25 Jul 19
Alkermes Plc Reports Second Quarter 2019 Financial Results
7:05am
8-K
EX-99.1
b14wghxy
15 Jul 19
Regulation FD Disclosure
7:33am
8-K
EX-99.1
922rlymiskc6hjf
25 Apr 19
Alkermes Plc Reports First Quarter 2019 Financial Results
7:05am
8-K
EX-99.1
77qrggkrwe1u
8 Apr 19
Alkermes Announces Departure of Jim Robinson
5:26pm
8-K
EX-99.1
21q8w
14 Feb 19
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
wpg98ebu rs9
1 Feb 19
Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
4:33pm